When it comes to TRK-fusion GISTs, first studies prove the good antitumor efficacy, a high and durable clinical response rate and good toleration of treatment with larotrectinib and entrectinib, NTRK inhibitors, both in adults and children, including recurrent or refractory neoplasms (e.g., NCT02122913, NCT02637687 and NCT02576431 involved 3 cases of GIST) [60,61]. Here, TPM3 is linked to neoplasm.